ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants

    NEXT STORY
    New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder
    PREV STORY
    ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants

    NEXT STORY
    New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder
    PREV STORY
    ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Cellectis Reports Clinical Hold Placed on MELANI-01 Study

    author_avatar
    NASDAQ Market News

    IRIDEX’s MicroPulse® Laser Technology Featured in Several Glaucoma and Retina Research Presentations at Major Ophthalmic Industry Conferences

    author_avatar
    NASDAQ Market News

    Patriot Reports 1st Quarter 2020 Loan Growth, and Deposit Growth offset by impact of COVID-19 Precautions and Provisions

    author_avatar
    NASDAQ Market News